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7.003
338 D.A. Maharem et al.fetuin-A and its gene and VC and also with bone mineral density (BMD) in patients with CKD on
conservative treatment, on maintenance of hemodialysis (HD) and those who underwent renal
transplantation.
This study included twenty eight CKD patients on HD, seventeen CKD patients on conservative
treatment and twelve patients who underwent transplantation in addition to sixteen healthy con-
trols. All were subjected to history taking, clinical examination, laboratory investigations including
fasting serum glucose, urea, creatinine, albumin, lipid proﬁle, C-reactive protein (CRP), estimated
glomerular ﬁlteration rate (e-GFR), calcium, phosphorus, calcium by phosphorus product
(Ca·PO4), intact parathyroid hormone (iPTH), alkaline phosphatase (Alk), fetuin-A and genotyp-
ing for the common functional polymorphisms on fetuin-A (Thr256Ser) using the Polymerase chain
reaction (PCR) technique. Radiological examination included ultrasonography of carotid arteries
and assessment of VC by plain X-ray and assessment of BMD.
Serum calcium was lower, phosphorus, Ca·PO4, iPTH and Alk were higher in all patient groups
than control. Fetuin-A was lower in all patient groups compared to controls. VC was detected in
39.2% HD patients, 29.4% patients on conservative treatment and 25% patients on transplanta-
tion. T-score of BMD was signiﬁcantly lower in all patient groups than control. There was no sta-
tistically signiﬁcant difference between patients and control groups according to the frequencies of
the three fetuin-A genotypes (Cﬁ G) but the distribution of the fetuin-A (Cﬁ G); Thr256Ser gene
polymorphisms in the studied subjects showed signiﬁcant correlation with low serum fetuin-A lev-
els. VC was associated with older age, male gender, longer HD duration, lower albumin, higher
LDL-c, higher carotid plaques and lower T-score value of BMD.
VC was evident in patients with CKD and it is related to atherosclerosis and lower BMD. Fetuin-
A was lower in all patients with CKD with signiﬁcant relation between serum fetuin-A level and its
gene polymorphism but not with VC.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Chronic kidney disease (CKD) is associated with increasing
risk for cardiovascular disease (CVD) and cardiovascular
events, even a slight reduction in glomerular ﬁltration rate
(GFR) is associated with a signiﬁcant increase in cardiovascu-
lar risk [1,2]. Up to 45% of pre-dialysis CKD patients may die
before reaching end-stage renal disease (ESRD), with CVD
being the leading cause of death with increasing risk in ESRD
patients [3,4].
Despite an improvement in survival after renal transplanta-
tion, renal transplant recipients (RTRs) remain at an increased
risk for CVD [5].
Vascular calciﬁcation (VC) is a strong independent risk fac-
tor for CV mortality [6]. VC may promote arterial stiffness,
which leads to increased pulse pressure, left ventricular hyper-
trophy and cardiovascular events [7,8].
The pathogenesis of VC is complex and not fully under-
stood. Numerous risk factors have been reported, some of
these are classic such as ageing, hypertension, diabetes, smok-
ing and dyslipidemia [9,10]; certain others are more speciﬁc to
CKD, such as mineral metabolism abnormalities, particularly
hyperphosphatemia, extreme parathyroid hormone, serum lev-
els or excess administration of calcium salts and dialysis dura-
tion [10,11].
There are two main types of VC, intimal and medial calci-
ﬁcations (Monckeberg’s medial sclerosis). Both types of calci-
ﬁcations are present in patients with CKD, but the
complications of these two types of VC are different: The for-
mer is related to calciﬁcation of the atherosclerotic plaque and
is mainly associated with occlusion of the vessels, and the latter
is associated with vascular stiffness; both are responsible for
the increased mortality in patients with CKD [12].VC is a pathological process occurring in response to an
inappropriate environmental milieu [13]. It does not consist
of a simple precipitation of calcium and phosphate but is in-
stead an active and modiﬁable process in which, step by step,
the vascular smooth cells undergo apoptosis and vesicle forma-
tion changes the phenotype of smooth vascular cells into
osteoblast like cells capable of undergoing the mineralization
process [12,14].
There are multiple inhibitors of VC such as matrix GLA
protein (MGP), osteoprotegerin (OPG), pyrophosphates and
fetuin-A [15,16]. Animal knockout models have shown that
key gene products may be protective of VC including MGP,
OPG and fetuin-A [17–19].
Fetuin-A is a hepatically synthesized 62-kDa {also called
alpha2-Heremans Schmid glycoprotein (AHSG)} and a nega-
tive acute phase reactant; it is a member of the cystatin super-
family of cysteine protease inhibitors [20,21]. It is a carrier for
growth factors, binds to and inactivates transforming growth
factor (TGF)-b and bone morphogenic protein, and is a major
component of mineralized bone. It decreases macrophage acti-
vation and release of proinﬂammatory cytokines [22,23]. Fet-
uin-A interacts with small mineral nuclei to form soluble
colloidal particles thereby preventing the precipitation of basic
calcium phosphate (BCP) and acting as a calciﬁcation inhibitor
in the supersaturated extracellular environment [24]. Conse-
quentially, fetuin-A can inhibit calciﬁcation in circulation
without affecting the normal bone mineralization [25]. In addi-
tion, at the cellular level, fetuin-A inhibits apoptosis of vascu-
lar smooth muscle cells (VSMCs), it also aids in the binding of
apoptotic bodies to neighboring cells leading to their clearance
and thereby reducing the potential for these substances to
nucleate BCP [26,27]. Fetuin-A is also known to inhibit the
insulin stimulated tyrosine kinase receptor and has been shown
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risk factor for the development of type 2 diabetes mellitus
[28,29].
In CKD patients, serum level of fetuin-A is signiﬁcantly
lower than in healthy control subjects [30]. Speciﬁc polymor-
phisms of fetuin-A gene were demonstrated to inﬂuence circu-
lating levels of fetuin-A [31]. However others concluded that
the distribution of the fetuin-A (Cﬁ G); gene polymorphisms
does not affect serum fetuin-A levels [32].
Ketteler et al. demonstrated a relationship between all cause/
cardiovascularmortality and low serum fetuin-A inHDpatients
[33]. Some studies permit consideration of fetuin-A as the
missing link between inﬂammation, atherosclerosis and
calciﬁcation in patients with CKD, extending the previously
known term ‘‘malnutrition-inﬂammation-atherosclerosis
syndrome’’ to ‘‘malnutrition-inﬂammation-atherosclerosis-
calciﬁcation syndrome’’ [34,35]. Hernandez et al. considered
that the presence of preexisting VCs may be associated
with an increased cardiovascular risk after renal transplantation
[36].
Patients with CKD show VCs almost in all localizations,
from high caliber arteries such as aorta, where the preva-
lence is extremely high, to medium and small sized vessels,
including coronary arteries. Also calciﬁcation of the cardiac
valves represents a high risk for cardiovascular dysfunction
[37].
VCs can be evaluated by different methods: ultrasonogra-
phy, electron beam computed tomography (EBCT), multislice
computed tomography or plain X-ray. Although the plain
X-ray approach might be relatively crude but it has the advan-
tages of being simple, cheap and applicable in daily clinical
practice [13,38,39].
Low bone mineral content at menopause has been shown to
be a risk factor for increased cardiovascular mortality later in
life [40]. Patients with severe VCs were associated with a higher
prevalence of any osteoporotic fracture. In addition, the pro-
gression of the aortic vascular calciﬁcations was associated
with the rate of decline in BMD at the lumbar spine [41].
Low bone density has also been associated with aortic calciﬁ-
cation, as detected by conventional X-ray and with surrogate
markers of subclinical vascular disease [42]. An association
between VC, vertebral fractures and mortality has been found
in patients on HD [43].
The term chronic kidney disease–mineral and bone disorder
(CKD–MBD) has been applied to the disturbance of mineral
metabolism, renal bone disease and VC, together with patient
level outcomes of fracture, CVD and mortality in patients with
CKD [44].
2. Aim of the work
The aim of this work was to study the association between ser-
um fetuin-A level and its gene and vascular calciﬁcation as well
as with bone mineral density in patients with CKD on conser-
vative treatment, on maintenance HD and those who under-
went renal transplantation.3. Subjects and methods
The present study included four groups of subjects: Patients
with chronic kidney disease were selected from nephrologywards, outpatients clinics and the hemodialysis unit at the
Nephrology Department, Medical Research Institute, Alexan-
dria University, Egypt. The study protocol was conducted
according to the Helsinki Declaration. Informed consent was
obtained from all the recruited subjects prior to their inclusion
in the study and approved by the Clinical Research Ethics
Committee of the Medical Research Institute.
Patients were divided into three groups. Twenty eight pa-
tients were receiving 4 h HD sessions, three times weekly for
more than 6 months, with bicarbonate dialysate using polysul-
phon dialyzer (Group I), seventeen patients were on conserva-
tive treatment (stages 3,4) (Group II), twelve patients
underwent transplantation (Group III), all of the kidney trans-
plant recipients were on a triple immunosuppression regimen
consisting of prednisolone, cyclosporine and mycophenolate
mofetil or azathioprine.
Subjects underwent a 2-week washout period, in which all
phosphate binders were withheld. None of the patients had
ever been treated with bisphosphonates.
Sixteen healthy volunteers were taken as control group
(Group IV).
Patients with diabetes mellitus, liver disease, active infec-
tion or overt inﬂammation and malignancies were excluded
from the study.
The studied groups were subjected to the following:
I- Detailed medical history taking; stressing on bone aches
and history of fracture and clinical examination was per-
formed after taking an informed consent from each
subject.
II- Calculation of body mass index (BMI) (weight in kilo-
grams/height in meters squared) [45].
III- Laboratory investigations:
(A) Specimen collection, storage and preparation: Five millili-
ters of venous blood were withdrawn from every patient
and control in the morning after over night fasting.
500 ll whole blood was separated in an eppendorf con-
taining ethylenediamine tetraacetic acid (EDTA) 5%
and stored at 20 C for genotyping for the common
functional polymorphisms on fetuin-A (Thr256Ser)
using Polymerase chain reaction (PCR) technique. The
remaining sample was transferred into a disposable plas-
tic tube and allowed to clot, then was centrifuged at
1200 rpm for 10–15 min to separate the serum. The
serum was then divided into three aliquots which were
kept frozen at 20 C until use. The following labora-
tory investigations were carried out:
(B) Routine laboratory investigations: They included estima-
tion of fasting serum glucose, urea, creatinine, triglycer-
ides, total cholesterol and high-density lipoprotein
(HDL) cholesterol using enzymatic colorimetric meth-
ods. Low-density lipoprotein (LDL) cholesterol was cal-
culated by the Friedewald’s formula. Also, total
calcium, phosphorus, alkaline phosphatase and serum
albumin were measured. Determination of routine bio-
chemical parameters was performed with standard tech-
niques by using the auto-analyzer OLYMPUS AU400,
using reconstituted freeze dried forms of multi-analyte
calibrators for the serum samples [46,47].
(C) Intact parathyroid-hormone (i-PTH) was measured by
chemiluminescent immunometric assay on IMMULITE
1000 autoanalyzer [48].
340 D.A. Maharem et al.(D) Estimation of the glomerular ﬁlteration rate (GFR) from
the plasma creatinine with the simpliﬁed Modiﬁcation of
diet in renal disease (MDRD) formula: GFR (ml/min/
1.73 m2 body surface area) = 175 · (serum creatinine,
in mg/dl)1.154 · (age)0.203 · (0.742, if female)
or · (1.212, if African American) [49].
(E) Speciﬁc laboratory tests:
1. Quantitative analysis of fetuin-A: Serum fetuin-A level
was measured using the ELISA technique (BioVendor
Human Fetuin-A ELISA,Germany) following the
instructions of the manufacturer [50].
2. DNA extraction and genotyping for the common func-
tional polymorphisms on fetuin-A (Thr256Ser) using the
PCR technique [51].
DNA was extracted from peripheral blood leucocytes from
the freshly withdrawn whole blood, using GeneJETGenomic
DNA Puriﬁcation Kit, Fermentas. (i)The purity and concentra-
tion of extracted genomic DNA were determined using the
Thermo Scientiﬁc NanoDrop 1000 Spectrophotometer
(Thermo Fisher Scientiﬁc,Wilmington, Delaware USA). Poly-
merase chain reaction and Restriction fragment length poly-
morphism (PCR/RFLP) techniques were used to detect
fetuin-A gene (Thr256Ser) polymorphism. PCR ampliﬁcation
of extracted DNA was done in a total volume of 25 ll (5 ll ex-
tracted DNA was mixed with 1 ll of each forward and reverse
primer and 12.5 ll DreamTaq Green PCR Master Mix (2·)
and completed to 25 ll with nuclease-free water).The primers
used (purchased from Fermentas Life Sciences.) were: F5-
GTCACCCCTCCTTGTAAC-3 (sense)[Tm = 45.6 C] Re-
verse primer antisense: R5-CCCCAATGAGACCACA-3
(Antisense) [Tm = 46 C] PCR was done on the thermal cycler
(Biometra) and the reaction conditions were as follows: initial
denaturation at 95 C for 5 min then 35 cycles of denaturation
at 94 C for 1 min, annealing at 59 C for 1 min, extension at
72 C for 1 min and ﬁnal extension at 72 C for 15 min.
For mutational analysis of fetuin-A Thr256Ser
(c.766C>G) at Sac I recognition site; FastDigest SacI restric-
tion enzyme 100 ll (from Fermentas Life Sciences) was used.
10 ll of each PCR product was mixed with FastDigest
enzyme 1 ll with FastDigest buffer 2 ll and completed to a
total volume of 30 ll with nuclease-free water. They were
mixed gently and incubated at 37 C for 60 min.
The digested products were separated on 1.5% agarose gel.
Allele C does not contain the SacI site, remains undigested as
405 bp fragments, whereas the allele G yields 193- and 212-bp
fragments. There are three possible genotypes for the fetuin-A:
Thr/Thr (Allele C), Thr/Ser (heterozygote) and Ser/Ser (Allele
G); (homozygote for absence of the Sac I site, heterozygote
and homozygote for the presence of the Sac I site; respectively)
[51] (Fig. 1).
IV. Radiological investigations:
1- Carotid ultrasonography for the measurement of
intima-media thickness (IMT) and the presence of ath-
erosclerotic plaques [52].
2- Vascular calciﬁcation (VC) was evaluated by a simple
vascular calciﬁcation score (SVCS) which is based on
the analysis of plain radiographic ﬁlms of the pelvis
and hand. Pelvis ﬁlms were divided into four sections
by two imaginary lines: a horizontal line over theupper limit of both femoral heads and a median verti-
cal line over the vertebral column. Hand ﬁlms were
divided for each hand by a horizontal line over the
upper limit of the metacarpal bones. Pelvis ﬁlms eval-
uated iliac and femoral arteries (ileo-femoral score)
and hand ﬁlms evaluated radial and digital arteries
(hand score). The presence of vascular calciﬁcations
in each section was rated as 1 and its absence as 0.
The ﬁnal score was the sum of all sections and ranged
from 0 to 8 [53].
3- The dual X-ray absorptiometry device to assess bone
mineral density (BMD), was calculated at the lumbar
spine and the femoral neck (g/cm2), it was expressed in
standard deviation (SD) units as T-scores (comparison
with the mean bone density in young adults) and Z-
scores (comparison with age matched mean). According
to the World Health Organization, BMD in any adult
that is between 1 and 2.5 SD below the mean is deﬁned
as osteopenia, and a value more than 2.5 SD below the
mean is deﬁned as osteoporosis [54].
4. Statistical analysis
Study data were statistically analyzed using the Statistical
Package for Social version program (SPSS program-version
18.0 – SPSS Inc., Chicago, IL. USA). Quantitative data were
expressed as median, minimum and maximum as well as
mean ± Standard deviation (SD). Patients were studied as
a group, and successively divided into three groups. Qualita-
tive data were described using number and percent. Associa-
tion between categorical variables was tested using the
Chi-square test. When more than 20% of the cells have an
expected count less than 5, correction for chi-square was con-
ducted using the Firsher’s Exact test or the Monte Carlo
correction.
The distributions of quantitative variables were tested for
normality using Kolmogorov–Smirnov’s test, Shapiro–Wilk’s
test. D’Agstino test was used if there was a conﬂict between
the two previous tests. If they reveal normal data distribution,
parametric tests were applied. If the data were abnormally dis-
tributed, non-parametric tests were used.
For normally distributed data, comparison between two
independent populations was done using the independent t-test
while more than two populations were analyzed by the F-test
(ANOVA) and the Post Hoc test (LSD).
For abnormally distributed data, Mann–Whitney’s Test
(for data distribution that was signiﬁcantly deviated from nor-
mal) was used to analyze two independent populations. If
more than two populations were analyzed, the Wallis test
was used.
Correlations between variables were assessed using the
Spearman or Pearson’s correlation coefﬁcient. A P value of
less than 0.05 was judged to be signiﬁcant.
5. Results
The present study included CKD patients, twenty eight on
HD, seventeen on conservative treatment, and twelve trans-
planted patients with sixteen subjects as the control group.
They were of matched age and sex (Table 1).
1 2 3 4 5 6 7 8 9 10 11 12 13
Figure 1 Ethidium bromide stained agarose gel electrophoresis of PCR ampliﬁed fetuin-A gene(Cﬁ G); Thr256Ser following sac I
restriction digestion for some samples. Showing: Lane 13: DNA size marker 50–1000 bp. Lane 9: Allele G (Ser/Ser) homozygote for the
presence of the sacI site which digests the 405 bp fragment into 193 and 212 bp fragments in a homozygote patient. Lane
1,2,3,5,6,7,8,10,11,12: Allele C (Thr/Thr) undigested as 405 bp. fragments homozygote for absence of the sacI site. Lane4: heterozygote
patient (Thr/Ser).
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tients (53.5%) it was hypertension, in 3 patients (10.7%) it
was chronic pyelonephritis, in 1 patient (3.6%) it was analgesic
nephropathy, in 1 patient (3.6%) it was the nephritic syn-
drome, in 1 patient (3.6%) it was polycystic kidney, in 1 pa-
tient (3.6%) it was renal amyloidosis, in 1 patient (3.6%) it
was congenital and in 5 patients (17.9%) it was of unknown
etiology.
Twenty one patients on HD (75%) were complaining of
bone ache with a history of fracture in one patient only
(3.6%); ten patients on conservative treatment (58.8%) and
only three patients in the transplanted group (25%) were com-
plaining of bone ache.
In the HD group, ﬁfteen patients (53.6%) were hyperten-
sive; ten patients on conservative treatment (58.8%) were
hypertensive and three patients in the transplanted group
(25%) were hypertensive. In the HD group, seven patients
(25%) had clinical manifestations and ECG changes of IHD;
in those on conservative treatment, ﬁve patients had IHD
(29.4%) while in the transplanted group, only two patients
(16.7%) had IHD.
Duration of HD was 63.46 ± 54.14 months while the dura-
tion of transplantation was 31.17 ± 11.17 months.
Serum albumin was signiﬁcantly lower in groups I, II and
III patients than in the controls (Table 2).
Total cholesterol and LDL-c were signiﬁcantly higher in
group III than in the control group, also LDL-c was signiﬁ-
cantly higher in group I and II than the control group.
HDL-c was signiﬁcantly lower in group I and II than in the
control group and TG was signiﬁcantly higher in group IIIthan the control group. CRP was signiﬁcantly higher in group
I and II but not in group III than in the control group. e-GFR
was signiﬁcantly lower in all patient groups than in the control
group (Table 3).
Serum calcium was signiﬁcantly lower in all patient groups
than in the control group, serum phosphorus and Ca·PO4,
iPTH, and Alk were signiﬁcantly higher in all patient groups
than in the control group. Serum fetuin-A was signiﬁcantly
lower in groups I, II and III than in the control group
(Table 4).
IMT was signiﬁcantly higher in all patient groups than in
the control group. Plaques were detected in eight patients
(28.6%) on HD, in four patients (23.5%) on conservative
treatment and in only two patients (16.7%) who underwent
transplantation. (Fig. 2). l Vascular calciﬁcation was detected
in eleven HD patients (39.3%), ﬁve patients on conservative
treatment (29.4%) and three transplanted patients (25%)
(Table 5).
As regards BMD of the arm, it was signiﬁcantly lower in
group I, II and III than in the control group but reach a
signiﬁcant value only in group III (P2 = 0.023
*). BMD of
the pelvis was lower in all patient groups than in the control
group but was of signiﬁcant value in groups I and III only
(P= 0.048*, P2 = 0.026
* respectively).BMD of the lumbar
spine was lower in all patient groups than in the control
group but of signiﬁcant value in group I only (P= 0.0016*).
T-score was signiﬁcantly lower in all patient groups than in
the control group and the Z-score was signiﬁcantly lower in
group I and III (P< 0.001*, P2 < 0.001
* respectively)
(Table 6).
Table 2 Laboratory investigations in patient and control groups.
Group I (n= 28) Group II (n= 17) Group III (n= 12) Group IV (n= 16) Test of sig. P value
FBS (mg/dl)
Min–Max 76.0–111.0 89.0–109.0 83.0–102.0 70.0–92.0 t= 4.153 P< 0.001*
Mean ± SD 92.79 ± 12.07 98.53 ± 6.38 94.58 ± 6.40 81.56 ± 5.80 t= 7.976 P1 < 0.001
*
Median 90.0 99.0 96.0 82.50 t= 5.626 P2 < 0.001
*
Creatinine (mg/dl)
Min–Max 3.60–16.50 4.0–8.10 1.0–1.90 0.80–1.0 Z= 5.235 P< 0.001*
Mean ± SD 8.46 ± 3.27 5.20 ± 1.38 1.48 ± 0.29 0.86 ± 0.06 Z= 3.803 P1 < 0.001
*
Median 8.10 4.80 1.45 0.90 Z= 0.883 P2 < 0.377
Urea (mg/dl)
Min–Max 80.0–207.0 85.0–140.0 30.0–108.0 19.0–40.0 t= 17.411 P< 0.001*
Mean ± SD 139.04 ± 32.80 106.65 ± 15.92 64.25 ± 25.02 28.31 ± 5.69 t= 19.040 P1 < 0.001
*
Median 145.0 102.0 60.0 28.50 t= 4.883 P2 < 0.001
*
Albumin (mg/dl)
Min–Max 1.30–4.50 2.60–4.30 3.0–4.30 3.60–4.80 t= 5.632 P< 0.001*
Mean ± SD 3.26 ± 0.75 3.38 ± 0.53 3.66 ± 0.41 4.17 ± 0.31 t= 5.253 P1 < 0.001
*
Median 3.25 3.20 3.70 4.15 t= 3.727 P2 < 0.001
*
t: Student’s t-test; Z: Mann Whitney’s test.
FBS = Fasting blood sugar.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
P=Comparison between control and group I; P1 = Comparison between control and group II.
P2 = Comparison between control and group III.
* Statistically signiﬁcant at P 6 0.05.
Table 1 Demographic data of ESRD patients and control groups.
Group I (n= 28) Group II (n= 17) Group III (n= 12) Group IV (n= 16) Test of sig. P value
Sex
Male 11 (39.3%) 8 (47.1%) 4 (33.3%) 7 (43.8%) v2 = 0.084 P= 0.772
Female 17 (60.7%) 9 (52.9%) 8 (66.7%) 9 (56.3%) v2 = 0.036 P1 = 0.849
FEp P2 = 0.705
Age (years)
Min–Max 21.0–75.0 25.0–80.0 46.0–60.0 27.0–55.0 t= 0.354 P= 0.725
Mean ± SD 43.86 ± 11.59 50.71 ± 13.57 52.25 ± 4.39 42.69 ± 8.32 t= 2.030 P1 = 0.051
Median 41.0 54.0 52.0 43.50 t= 3.927 P2 = 0.001
*
BMI (kg/m)
Min–Max 12.03–36.50 22.10–41.90 21.10–34.70 21.90–28.10 t= 0.530 P= 0.599
Mean ± SD 23.65 ± 5.93 28.09 ± 4.67 27.49 ± 3.70 24.29 ± 1.90 t= 3.024 P1 = 0.005
*
Median 23.0 27.30 27.90 24.05 t= 2.976 P2 = 0.006
*
MBP (mmHg)
Min–Max 83.30–116.60 80.0–123.30 90.0–118.30 80.0 ± 93.30 t= 6.005 P= 0.000*
Mean ± SD 101.39 ± 8.39 107.33 ± 14.19 98.99 ± 8.87 87.39 ± 5.33 t= 5.402 P1 = 0.000
*
Median 103.30 113.30 94.95 89.30 t= 4.314 P2 = 0.003
*
SBP (mmHg)
Min–Max 110.0–160.0 100.0–170.0 120.0–155.0 100.0–125.0 t= 4.809 P= 0.000*
Mean ± SD 132.50 ± 13.51 141.47 ± 20.52 130.42 ± 11.96 114.06 ± 9.53 t= 4.967 P1 = 0.000
*
Median 130.0 150.0 127.50 117.50 t= 4.314 P2 = 0.001
*
v2: Chi square test; t: Student’s t-test.
FE: Fisher’s exact test.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
ESRD= End stage renal disease; BMI = Body mass index; MBP=Mean blood pressure; SBP = Systolic blood pressure.
P=Comparison between control and group I; P1 = Comparison between control and group II.
P2 = Comparison between control and group III.
* Statistically signiﬁcant at P 6 0.05.
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Table 3 Lipid proﬁle, CRP and e-GFR in patient and control groups.
Group I (n= 28) Group II (n= 17) Group III (n= 12) Group IV (n= 16) Test of sig. P value
T.Cholesterol (mg/dl)
Min–Max 103.0–259.0 115.0–254.0 176.0–203.0 99.20–189.90 Z= 0.171 P= 0.864
Mean ± SD 163.43 ± 43.07 165.47 ± 38.21 190.58 ± 9.08 154.60 ± 22.55 Z= 0.613 P1 = 0.540
Median 150.50 160.0 190.0 158.50 Z= 4.137 P2 < 0.001
*
LDL-c (mg/dl)
Min–Max 59.0–171.0 55.0–202.0 109.0–135.0 34.44–105.40 t= 2.538 P= 0.015*
Mean ± SD 105.29 ± 32.01 111.00 ± 42.73 121.50 ± 8.70 82.53 ± 21.13 t= 2.447 P1 = 0.022
*
Median 98.0 105.0 122.0 91.42 t= 6.660 P2 = 0.001
*
HDL-c(mg/dl)
Min–Max 13.0–42.0 22.0–57.0 42.0–67.0 32.50–71.0 Z= 4.041 P< 0.001*
Mean ± SD 34.68 ± 12.96 35.18 ± 11.71 53.08 ± 7.27 53.04 ± 10.73 Z= 3.861 P1 < 0.001
*
Median 31.0 30.0 53.0 54.90 Z= 0.628 P2 = 0.530
TG (mg/dl)
Min–Max 54.0–234.0 45.0–225.0 85.0–250.0 63.0–141.0 Z= 0.854 P= 0.393
Mean ± SD 117.75 ± 50.77 119.06 ± 53.54 185.08 ± 42.57 98.11 ± 2.85 Z= 0.955 P1 = 0.339
Median 107.0 113.0 187.50 98.50 Z= 3.902 P2 < 0.001
*
CRP (mg/dl)
Min–Max 3.40–90.0 1.90–43.50 2.10–4.70 1.40–4.10 Z= 5.235 P< 0.001*
Mean ± SD 32.57 ± 21.41 14.19 ± 10.65 3.32 ± 0.89 3.01 ± 0.87 Z= 3.803 P1 < 0.001
*
Median 29.05 13.60 3.05 3.15 Z= 0.883 P2 = 0.377
e-GFR (ml/min)
Min–Max 4.0–11.0 14.0–29.0 43.0–119.0 100.0–128.0 Z= 5.493 P< 0.001*
Mean ± SD 7.25 ± 2.27 20.76 ± 4.31 64.75 ± 26.57 115.44 ± 9.19 Z= 4.907 P1 < 0.001
*
Median 6.0 20.0 49.50 118.0 Z= 3.841 P2 < 0.001
*
t: Student t-test; Z: Mann Whitney’s test.
*Statistically signiﬁcant at P 6 0.05.
T.Cholesterol = Total cholesterol; LDL-c = Low density lipoprotein cholesterol.
HDL-c = High density lipoprotein cholesterol; TG= Triglycerides.
CRP = C-reactive protein; e-GFR= estimated glomerular ﬁltration rate.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
P=Comparison between control and group I; P1 = Comparison between control and group II.
P2 = Comparison between control and group III.
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morphisms, there was no statistically signiﬁcant difference be-
tween patients of three groups and the control group or
between patients as a whole and control according to the fre-
quencies of the three fetuin-A genotype polymorphisms
(Cﬁ G) (Tables 7 and 8).
Serum fetuin-A was signiﬁcantly negatively correlated with
IMT, BMD at spine and Z-score and positively correlated with
HDL-c level but no signiﬁcant correlation was found between
fetuin-A and the duration of HD or transplantation. No signif-
icant correlation was found between fetuin-A and serum Ca,
PO4, ALk, iPTH and e-GFR.
The negative correlation between fetuin-A and CRP and
also between it and the T-score of BMD did not reach a signif-
icant value.
There was a statistical signiﬁcant association between fet-
uin-A gene polymorphisms and the serum fetuin-A level as
subjects with CG and GG genotypes had lower fetuin-A levels
than those with the CC genotype (Table 9 and Fig. 3). How-
ever, no signiﬁcant difference was found between fetuin-A
genotypes as regards serum Ca, Po4, Alk, iPTH, CRP, IMT
and BMD.e-GFR was signiﬁcantly negatively correlated with PO4
(r= 0.372, P= 0.004*); Ca·PO4 (r= 0.303, P=
0.022*); CRP (r= 0.727, P< 0.001*) and Alk (r= 0.622,
P< 0.001*).
CRP was signiﬁcantly positively correlated with PO4
(r= 0.314, P= 0.018*); Alk (r= 0.521, P< 0.001*) and
iPTH (r= 0.442, P= 0.001*) and a signiﬁcant negative corre-
lation with albumin (r= 0.275, P= 0.038*) was seen also
CRP had a signiﬁcant negative correlation with BMD at the
arm and pelvis (r= 0.347, P= 0.008*; r= 0.424,
P= 0.001* respectively). IMT showed a signiﬁcant positive
correlation with PO4 (r= 0.289, P= 0.029*).
VC was signiﬁcantly associated with older age, male gen-
der, longer HD duration, lower albumin, higher LDL-c, higher
carotid plaques and lower BMD at the lumbar spine and the T-
score value but had no signiﬁcant association with the follow-
ing parameters: duration of transplantation, blood pressure,
total cholesterol, TG, Ca, PO4, Ca·PO4, iPTH, CRP, fetuin
A, e-GFR and IMT. Also no signiﬁcant association was seen
between fetuin-A gene polymorphism and VC. Patients with
VC had higher CRP than those without but did not reach a
signiﬁcant value. (Table 10).
Table 4 Serum Ca, PO4, Ca·PO4, iPTH, alkaline phosphatase and fetuin-A in patient and controls groups.
Group I (n= 28) Group II (n= 17) Group III (n= 12) Group IV (n= 16) Test of sig. P value
S.Ca (mg/dl)
Min–Max 5.80–13.10 6.70–9.60 8.10–10.20 8.70–10.30 t= 3.681 P= 0.001*
Mean ± SD 8.56 ± 1.41 8.01 ± 0.97 8.78 ± 0.59 9.63 ± 0.44 t= 6.235 P1 < 0.001
*
Median 8.55 8.10 8.70 9.65 t= 4.407 P2 < 0.001
*
S.PO4(mg/dl)
Min–Max 3.50–9.40 3.20–7.10 3.70–4.90 2.50–4.0 t= 7.376 P< 0.001*
Mean ± S.D 5.90 ± 1.71 5.48 ± 1.13 4.41 ± 0.45 3.36 ± 0.49 t= 4.663 P1 < 0.001
*
Median 5.80 5.60 4.50 3.40 t= 4.372 P2 < 0.001
*
Ca·PO4
Min–Max 27.01–77.29 26.24–64.32 30.34–43.12 24.0–40.40 t= 5.834 P< 0.001*
Mean ± S.D 49.99 ± 14.51 42.96 ± 12.63 38.61 ± 3.88 32.33 ± 5.13 t= 3.203 P1 = 0.004
*
Median 50.58 39.76 39.81 33.30 t= 3.541 P2 = 0.002
*
iPTH (pg/ml)
Min–Max 52.20–3300.0 23.0–536.0 38.50–190.0 16.0–42.0 Z= 5.466 P< 0.001*
Mean ± S.D 561.69 ± 632.17 239.64 ± 146.92 92.28 ± 47.33 28.81 ± 8.31 Z= 4.505 P1 < 0.001
*
Median 461.50 214.0 76.15 29.0 Z= 4.319 P2 < 0.001
*
Alk (U/L)
Min–Max 98.0–333.0 81.0–213.0 67.0–128.0 39.0–86.0 Z= 5.467 P< 0.001*
Mean ± SD 174.25 ± 62.24 119.76 ± 36.55 97.83 ± 19.78 61.44 ± 12.12 Z= 4.828 P1 < 0.001
*
Median 198.0 106.0 101.50 58.50 Z= 3.878 P2 < 0.001
*
Fetuin-A (g/l)
Min–Max 0.01–0.64 0.11–0.23 0.23–0.32 0.24–0.46 Z= 2.184 P= 0.029*
Mean ± S.D 0.26 ± 0.17 0.17 ± 0.04 0.28 ± 0.03 0.35 ± 0.06 Z= 4.900 P1 < 0.001
*
Median 0.26 0.18 0.28 0.35 Z= 3.065 P2 = 0.002
*
t: Student t-test; Z: Mann Whitney’s test.
S.Ca = Serum calcium; S.PO4 = Serum Phosphorus.
Ca·Ph = Calcium by Phosphorus product; Alk = Alkaline phosphatase.
iPTH= intact parathyroid hormone.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
P=Comparison between control and group I; P1 = Comparison between control and group II.
P2 = Comparison between control and group III.
* Statistically signiﬁcant at P 6 0.05.
344 D.A. Maharem et al.6. Discussion
CKD–MBD describes a triad of inter-related biochemical,
bone and vascular abnormalities that have been linked with in-
creased cardiovascular-related morbidity and mortality in pa-
tients with CKD and has been suggested as a non traditional
risk factor for CVD in these patients [55,56].
The VC is strong predictor of CVD and all cause mortality
not only in HD and peritoneal dialysis patients but also in
RTRs [35,57,58].
The inhibitory role of fetuin-A on VC may include the
inhibition of calcium phosphate precipitation in the
serum, binding of the bone derived hydroxyapatite and limita-
tion of dedifferentiation and apoptosis of the VSMCs
[19,27,59].
There was an association between bone fragility and VC
and this association was under-estimated because osteoporosis
and VC were considered non-modiﬁable disorders of ageing
[60]. It has been demonstrated that VC scores are associated
with low bone turnover and low bone volume in ESRD pa-
tients [11,61].In the present work, we studied the association between fet-
uin-A and its gene and both VC and BMD in patients with
CKD on conservative treatment, on maintenance HD and
those underwent renal transplantation.
Serum fetuin-A level was signiﬁcantly lower in all patient
groups than healthy controls. Other authors found similar re-
sults in ESRD patients before starting HD [30,32]. Also El-
Shehaby et al. revealed that lower serum fetuin-A in HD pa-
tients was signiﬁcantly associated with high calciﬁcation
scores [62] and Marechal et al. showed that low serum fet-
uin-A level was independently associated with aortic calciﬁca-
tions and a higher risk of cardiovascular events and deaths in
RTRs [63].
In our study, a semiquantitative assessment with plain X-
rays was done to detect VC. Although this approach might
be relatively crude and does not allow for differentiation be-
tween intimal and medial calciﬁcation, it has the advantages
of being simple, cheap and applicable in daily clinical practice
[12]. Although the use of more speciﬁc and sensitive techniques
such as EBCT or spiral computed tomography might have
added additional useful information, they are more sophisti-
Figure 2 Carotid Doppler showing calciﬁed plaque in haemodialyzed patient.
Table 5 Statistical analysis of radiological examination of ESRD patients and controls.
Group I (n= 28) Group II (n= 17) Group III (n= 12) Group IV (n= 16) Test of sig. P value
IMT (mm)
Min–Max 0.3–1.20 0.40–0.80 0.20–0.90 0.10–0.40 Z= 5.184 P< 0.001*
Mean ± S.D 0.68 ± 0.23 0.56 ± 0.13 0.60 ± 0.22 0.25 ± 0.10 Z= 4.735 P1 < 0.001
*
Median 0.65 0.50 0.60 0.25 Z= 3.876 P2 < 0.001
*
Plaques(+) 8 (28.6%) 4 (23.5%) 2 (16.7%) 0 (0.0) FEp P= 0.036*
P1 = 0.103
P2 = 0.175
VC
(+) 6 (21.4%) 3 (17.6%) 3 (25%) 0 (0.0) Z= 2.830 P= 0.005*
(++) 2 (7.1%) 2 (11.8%) 0 (0.0) 0 (0.0) Z= 2.312 P1=0.021
*
(+++) 2 (7.1%) 0 (0.0) 0 (0.0) 0 (0.0) Z= 2.078 P2 = 0.038
*
(++++) 1 (3.6%) 0 (0.0) 0 (0.0) 0 (0.0)
FE: Fisher’s exact test; Z: Mann Whitney’s test.
IMT= Intima media thickness; VC = Vascular calciﬁcation.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
P=Comparison between control and group I; P1 = Comparison between control and group II.
P2 = Comparison between control and group III.
* Statistically signiﬁcant at P 6 0.05.
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sonnel [36,64].
In the present study, VC was detected in 39.3% of HD pa-
tients, 29.4% of patients on conservative treatment and 25%
of those who underwent transplantation. Although other stud-
ies showed higher prevalence [6,65,66], this may be due to the
reduced sample of studied patients or the use of plain X-ray fordetection of VC and the use of more sensitive methods may
provide more detailed information about the extension of
VC in the arterial bed [64].
Blacher et al. demonstrated that 66% of HD patients had
VC in the common carotid artery, abdominal aorta or in the
iliofemoral vessels [6]. Higher percentage was reported by
Goodman et al. in young adults on HD treatment (90% of pa-
Table 6 Statistical analysis of bone mineral density results in patient and control groups.
Group I (n= 28) Group II (n= 17) Group III (n= 12) Group IV (n= 16) Test of sig. P value
Arms
Min–Max 2.50–0.87 0.60–0.97 0.71–1.02 1.80–2.20 Z= 1.771 P= 0.077
Mean ± S.D 0.65 ± 1.27 0.70 ± 0.40 0.83 ± 0.10 0.19 ± 1.07 Z= 1.893 P1 = 0.058
Median 0.60 0.83 0.84 0.10 Z= 2.278 P2 = 0.023*
Pelvis
Min–Max 3.50–1.10 0.80–1.21 0.95–1.22 2.10–2.90 Z= 1.978 P= 0.048*
Mean ± S.D 0.65 ± 1.51 0.84 ± 0.52 1.06 ± 0.08 0.54 ± 1.31 Z= 1.622 P1 = 0.105
Median 0.50 0.99 1.05 0.30 Z= 2.230 P2 = 0.026*
Spine
Min–Max 0.79–1.39 0.79–1.39 0.95–1.24 0.93–1.52 t= 2.515 P= 0.0016*
Mean ± S.D 1.0 ± 0.17 1.07 ± 0.16 1.06 ± 0.09 1.13 ± 0.17 t= 1.038 P1 = 0.307
Median 0.99 1.04 1.03 1.07 t= 1.548 P2 = 0.135
T-Score
Min–Max 3.50–1.19 2.70–1.40 1.10–1.10 0.82–1.50 Z= 3.748 P< 0.001*
Mean ± S.D 0.24 ± 1.74 0.05 ± 1.25 0.31 ± 0.68 1.15 ± 0.18 Z= 2.651 P1 = 0.008*
Median 0.87 0.20 0.40 1.09 Z= 4.068 P2 < 0.001*
Z-Score
Min–Max 2.5–1.40 2.30–1.50 2.40–1.20 0.64–1.27 Z= 4.037 P< 0.001*
Mean ± S.D 0.11 ± 1.37 0.09 ± 1.22 0.78 ± 1.03 0.89 ± 0.14 Z= 1.299 P1 = 0.194
Median 0.65 0.76 0.75 0.89 Z = 3.762 P2 < 0.001*
t: Student’s t-test; Z: Mann Whitney’s test.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
P=Comparison between control and group I; P1 = Comparison between control and group II.
P2 = Comparison between control and group III.
* Statistically signiﬁcant at P 6 0.05.
Table 7 Distribution of fetuin-A gene between the groups.
Group CC CG GG Test of sig.
Group I 17 (60.7%) 10 (35.7%) 1 (3.6%) v2 = 0.031 P1 = 0.860
Group II 10 (58.8%) 6 (35.3%) 1 (5.9%) v2 = 0.167 P2 = 0.683
Group III 7 (58.4%) 4 (33.3%) 1 (8.3%) FEP3 = 0.751
Group IV 12 (75%) 3 (18.8%) 1 (6.2%) v2 = 1.263 P4 = 0.261
MCp 0.893
v2: Chi square test; MC: Monte Carlo test.
Group I = Patients on HD; Group II = Patients on conservative treatment.
Group III = Patients after transplantation; Group IV = Control group.
P1 = Comparison between CC with each of CG and GG.
P2 = Comparison between CG and GG.
Table 8 Comparison between patients and control group
according to the frequencies of fetuin-A genotype polymor-
phisms (Cﬁ G).
Fetuin-A genotypes Patients Control v2 (P)
CC 34 (59.6%) 12 (75%) 1.263 (0.261)
CG 20 (35.1%) 3 (18.7%)
GG 3 (5.3%) 1 (6.3%)
v2: Chi square test between genotype CC and other genotypes
between patients and control.
346 D.A. Maharem et al.tients aged 20–30 years) [65]. Goldsmith et al. found that the
prevalence of VC increased from 39% at the start of dialysisto 92% after 16 years of HD [66], in another study Hernandez
et al. reported that 24.4% of renal transplant candidates had
VC on a plain abdominal or pelvic X-ray before renal trans-
plantation [36]. Although successful RT may improve some
risk factors associated with the uremic state, VC may extend
or at least do not regress in a considerable proportion of RTRs
and remain at an increased risk for CVD compared to the gen-
eral population [36].
In our study, BMD showed lower values in all patient
groups than the control which is similar to other results
[67,68]. Although low BMD is a common ﬁnding in dialysis
patients, Taal et al. demonstrated that dialysis patients with
bone loss have higher rates of cardiovascular death compared
with patients with normal BMD [69].
Table 9 Correlation of serum fetuin-A with different
parameters.
R P
Duration of HD (months) 0.010 0.961
Duration of transplantation (months) 0.207 0.519
Serum Ca (mg/dl) 0.246 0.065
Serum phosphorus (mg/dl) 0.026 0.849
iPTH (pg/ml) 0.034 0.800
Albumin (g/dl) 0.186 0.167
Alk (U/l) 0.100 0.461
LDL-c (mg/dl) 0.003 0.982
HDL-c (mg/dl) 0.319 0.016*
e-GFR (ml/min) 0.072 0.592
CRP (mg/dl) 0.096 0.475
IMT (mm) 0.296 0.025*
Arm (BMD) 0.214 0.109
Pelvis (BMD) 0.103 0.445
Spine (BMD) 0.355 0.007*
T-score (BMD) 0.180 0.181
Z-score (BMD) 0.277 0.037*
Fetuin genotype (CC/CG/GG) 0.246 0.036*
Fetuin genotype (CC/CG+GG) 0.244 0.038*
rs: Spearman coefﬁcient.
HD=Hemodialysis.
Alk = Alkaline phosphatase; iPTH= Intact parathyroid
hormone.
LDL-c = Low density lipoprotein cholesterol.
HDL-c = High density lipoprotein cholesterol.
e-GFR= estimated glomerular ﬁlteration rate; CRP = C. reactive
protein; IMT= Intima media thickness; BMD= Bone mineral
density.
* Statistically signiﬁcant at P 6 0.05.
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Figure 3 Univariate correlation between serum fetuin-A level
and fetuin-A genotypes in the studied subjects.
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control group with demonstration of plaques in 28.6% of
group I, 23.5% of group II and 16.7% of group III. These re-
sults were similar to other studies in CKD and HD patients[70,71]. Nafar et al. found that IMT increased over a short
time in RTRs [72].
Serum fetuin-A level did not show signiﬁcant correlation
with e-GFR, Ca, PO4, Ca·PO4, iPTH, Alk, CRP, albumin,
T-score of BMD or VC. It showed only a signiﬁcant negative
correlation with IMT.
Stenvinkel et al. found signiﬁcant correlation between the
fetuin-A level and both albumin and CRP and no signiﬁcant
correlation between the fetuin-A level and e-GFR [30]. Also
Ketteler et al. reported an inverse relationship between the
serum fetuin-A level and CRP [33]. Hamano et al. did not ﬁnd
a signiﬁcant correlation between the serum fetuin-A level and
CACS but found a signiﬁcant positive correlation between the
fetuin-A level and serum albumin [73]. Ford et al. demon-
strated that the fetuin-A level was correlated with PO4 but
not with CRP [20]. Moe et al. also found no correlation be-
tween the serum fetuin-A level and VC, serum levels of Ca,
PO4 or iPTH [13].
Jung et al. [74], Hermans et al. [75]and Ix et al. [76] reported
that low serum fetuin A is not an independent predictor of VC
in patients with CKD which was similar to our study.
The absence of signiﬁcant negative correlation between fet-
uin-A and CRP can be explained by the small number of pa-
tients studied and the large proportion of patients in whom
CRP was not elevated and we did not use the high sensitive
method for the detection of CRP. Our results were similar to
those observed by Schaalan et al. who demonstrated negative
correlation between CRP and fetuin-A that did not reach a sig-
niﬁcant value in HD children [77].
We observed that patients with VC had higher CRP levels
but with no statistically signiﬁcance difference compared with
patients without calciﬁcation. Other studies showed similar re-
sults [10,78,79]. DeLoach et al. found that CRP was associated
with the presence of aortic calciﬁcation at the time of trans-
plant and aortic calciﬁcation progression post transplant [5].
Turkmen et al. found no difference in the CRP level between
patients according to CACS in HD or PD patients [80]. It
was suggested that CRP may be one of the key mediators of
vessel wall calciﬁcation in HD patients [81]. Inﬂammation is
an integral component of atherosclerosis that may worsen in
severity by reducing fetuin-A synthesis and other circulating
calciﬁcation inhibiting factors [33] and the present work con-
ﬁrmed the association between higher CRP serum levels and
severe VC and also the negative signiﬁcant correlation between
fetuin-A and IMT as fetuin-A is regulated as a negative acute
phase protein and low fetuin-A and high CRP may represent
the same biological event [35].
Patients with VC were signiﬁcantly older, predominantly
male with a higher duration of HD, higher LDL-c, lower albu-
min level and lower BMD at the spine and lower T-score.
These results are in accordance with previous studies as Coll
et al. who demonstrated that patients with VC were signiﬁ-
cantly older, predominantly male but showed no differences
in time of dialysis, BMI, blood pressure and lipid proﬁle than
those without VC [78]. McCullough et al. concluded that CAC
was strongly correlated with older age, male gender and longer
time of dialysis [82].
Asci et al. also found that increasing CACs were associated
with older age, male gender, longer HD vintage and lower
albumin and that there were no statistically signiﬁcant differ-
ences between CACs and Ca, PO4, iPTH, triglycerides, total
Table 10 Demographic and biochemical characteristics of the study population according to vascular calciﬁcation.
Vascular calciﬁcation (n= 19) No vascular calciﬁcation (n= 38) Test of sig. P value
Male sex 11 (57.9%) 12 (31.6%) v2 = 3.645 P= 0.056
Age (years) 52.26 ± 9.77 45.37 ± 11.95 t= 2.175 P= 0.034*
BMI (kg/m2) 25.96 ± 4.94 25.69 ± 5.84 t= 0.176 P= 0.861
Hypertension 10 (52.6%) 18 (47.4%) v2 = 0.140 P= 0.708
IHD 4 (21.1%) 10 (26.3%) FEp P= 0.754
Duration of HD (months) 105.0 ± 64.43 36.59 ± 19.94 Z= 3.296 P= 0.001*
Duration of transplantation(months) 31.0 ± 10.58 31.22 ± 11.98 Z = 0.277 P= 0.782
MBP (mmHg) 102.25 ± 8.26 102.86 ± 12.0 t= 0.233 P= 0.825
SBP (mmHg) 132.63 ± 12.95 135.79 ± 17.42 t= 0.698 P= 0.488
FBS (mg/dl) 95.58 ± 10.35 94.53 ± 9.65 t= 0.379 P= 0.706
Urea (mg/dl) 123.37 ± 29.84 108.76 ± 43.31 t= 1.319 P= 0.193
Creatinine (mg/dl) 6.78 ± 3.41 5.63 ± 3.74 Z= 1.355 P= 0.175
Albumin (g/dl) 3.07 ± 0.68 3.53 ± 0.56 t= 2.722 P= 0.009*
T.cholesterol (mg/dl) 154.68 ± 35.23 117.29 ± 37.55 Z= 1.837 P= 0.066
LDL-c (mg/dl) 118.26 ± 32.73 94.68 ± 27.13 t= 2.706 P= 0.009*
HDL-c (mg/dl) 37.61 ± 12.36 40.89 ± 16.10 Z= 0.542 P= 0.588
TG (mg/dl) 138.76 ± 59.17 119.42 ± 49.15 Z= 1.117 P= 0.264
S.ca (mg/dl) 8.16 ± 0.98 8.58 ± 1.25 t= 1.281 P= 0.205
S.PO4 (mg/dl) 5.51 ± 1.52 4.82 ± 1.57 t= 1.642 P= 0.105
Ca·PO4 44.90 ± 13.42 41.80 ± 12.90 t= 0.891 P= 0.376
ALk (U/L) 150.47 ± 65.67 137.63 ± 54.89 Z= 0.847 P= 0.397
e-GFR (ml/min) 20.79 ± 27.52 24.68 ± 24.56 Z= 1.179 P= 0.238
CRP 28.40 ± 25.30 17.20 ± 15.92 Z= 1.727 P= 0.086
iPTH 372.71 ± 726.04 363.87 ± 325.23 Z= 0.821 P= 0.412
Fetuin A 0.27 ± 0.15 0.22 ± 0.12 Z= 0.973 P= 0.330
Fetuin-A genotype MCp P= 0.327
CC 22 (57.9%) 12 (63.2%)
CG 15 (39.5%) 5 (26.3%)
GG 1 (2.6%) 2 (10.5%)
IMT (mm) 0.67 ± 0.19 0.61 ± 0.21 Z= 1.192 P= 0.233
Plaques (+) 8 (42.1%) 6 (15.8%) v2 = 4.734 P= 0.03*
ARM 0.60 ± 0.61 0.20 ± 1.27 Z= 0.254 P= 0.799
Pelvis 0.78 ± 0.74 0.16 ± 1.48 Z= 1.407 P= 0.160
Spine 0.96 ± 0.13 1.07 ± 0.15 t= 2.837 P= 0.006*
T-score 1.64 ± 1.29 0.53 ± 0.78 Z= 5.289 P<0.001*
Z-score 1.28 ± 1.36 0.35 ± 0.82 Z= 4.056 P<0.001*
v2: Chi square test; MC: Monte Carlo test; FE: Fisher’s Exact test.
Z: Mann Whitney’s test; t: Student’s t-test.
BMI = Body mass index; IHD= Ischemic heart disease.
HD=Hemodialysis; MBP=Mean blood pressure; SBP = Systolic blood pressure; FBG= Fasting blood glucose.
T.Cholesterol = Total Cholesterol; LDL-c = Low density lipoprotein cholesterol.
HDL-c = High density lipoprotein cholesterol; TG= Triglycerides.
Ca·Po4 = Calcium by phosphorus product; ALK= Alkaline phosphatase.
e-GFR= estimated glomerular ﬁlteration rate; CRP = C-reactive protein.
iPTH= intact parathyroid hormone; IMT= Intima media thickness.
* Statistically signiﬁcant at P 6 0.05.
348 D.A. Maharem et al.cholesterol and CRP [83]. Moe et al. demonstrated that the
duration of dialysis and age were the only factors that were
correlated with coronary calciﬁcation and thus, it is tempting
to speculate that decreasing fetuin-A level during renal replace-
ment therapy may be one reason for accelerated VC [39].
In the present study, no signiﬁcant correlation was found
between VC and time of transplantation which may be ex-
plained by the small number of transplanted patients. Seyahi
et al. found that longer time of transplantation was associated
with CAC [2]. It was not clear whether the progression of CAC
slows down or reverses following renal transplantation. How-
ever the authors concluded that renal transplantation slows
down but does not halt CAC progression [2].We found that patients with VC had signiﬁcant lower albu-
min levels than those without. It was demonstrated that
advancement of VC in ESRD patients was associated with
inﬂammatory markers. Wang et al. conﬁrmed the link between
malnutrition, markers of inﬂammation, atherosclerotic vascu-
lar and cardiac calciﬁcation in PD patients and considered
changing the term to ‘‘malnutrition-inﬂammation-atheroscle-
rosis-calciﬁcation syndrome’’[35]. Although it was proposed
that disorders of mineral metabolism may play a role in the
genesis of VC in ESRD patients [73]. We observed no signiﬁ-
cant difference between patients with VC and those without
as regards Ca, Po4, Ca·Po4 product, Alk, iPTH and the serum
fetuin-A level although those with VC had lower Ca, higher
Association of serum fetuin-A and fetuin-A gene polymorphism in relation to mineral and bone disorders 349PO4 and higher iPTH but did not reach statistically signiﬁcant
results possibly due to reduced sample size. Barreto et al.
found no association between CACs and Po4, Ca, iPTH or
Alk [79].
Braun et al. failed to ﬁnd any relationship between various
parameters of calcium-phosphate balance, but they noticed
that the calcium score correlated with BMD in the lumbar
spine [84].
These ﬁndings suggest that bone metabolism and turnover
may affect the degree of mineral content deposition within the
vascular wall and this points to a possible relationship between
VC and bone turnover [34].
Rodriguez-Garcia et al. showed that only age and time on RT
were associated with an increased risk of VC and the prevalence
of vertebral fractures and serum Ca, PO4, Ca·PO4 and iPTH
were not signiﬁcantly associated with the prevalence of any type
of VC [43]. Also Seyahi et al. found similar results in RTRs [2].
Experimental data have clearly shown that VSMCs can
modify their phenotype becoming osteoblast like cells able to
induce VC .This fact has opened a fascinating area of research
between vascular and mineral metabolism [43].
The association between osteoporosis and VC was not
deﬁnitively explained and there is uncertainty whether the
two disease processes are truly linked. VC in and by itself
could affect bone metabolism; arterial stenosis could decrease
peripheral blood supply, suppressing bone cell function, or
atherosclerotic disease might limit physical activity, leading
to bone loss [85].
Inﬂammation may promote VC and osteoporosis has an
important inﬂammatory component, this might be part of
the pathway linking VC and bone loss [60].
It was demonstrated that patients with the highest degree of
aortic calciﬁcation had the lowest bone density and those with
the most severe aortic calciﬁcation had not only a lower bone
mass but also a higher incidence of new osteoporotic fractures
[61]. Rodriguez-Garcia et al. demonstrated that VC in medium
caliber arteries was associated with an increased risk of verte-
bral fractures but there was no relationship between VC and
peripheral osteoporotic fractures [43]. Asci et al. found a posi-
tive correlation between bone turnover and CAC [83].
In our study we demonstrated that patients with VC had
lower BMD than those without which was evident in the spine
and total T-score. Filgueira et al. concluded that low vertebral
bone density (VBD) was associated with the presence of CAC
in nondialyzed CKD patients and they suggested that low
VBD might constitute another nontraditional risk factor for
CVD in CKD patients considering that bone loss and CVD
share similar etiopathogenic mechanisms [86].
In an attempt to know more about the pathogenesis of in-
creased risk of VC and atherosclerosis in patients with CKD,
restriction enzyme analysis was done for the detection of
restriction fragment length of fetuin-A; (Cﬁ G);Thr256Ser
gene polymorphisms.
There was no statistically signiﬁcant difference between
CKD patients and the control group according to the frequen-
cies of the three fetuin-A genotype polymorphisms (Cﬁ G)
but there was a statistically signiﬁcant association between fet-
uin-A gene polymorphisms and the serum fetuin-A level as
subjects with CG and GG genotypes had lower fetuin-A level
than those with CC genotype.
Stenvinkel et al. demonstrated that Swedish dialysis patients
with fetuin-A 256Ser/Ser (allele G) had lower serum fetuin-Alevels and were associated with higher cardiovascular mortality
rate [30]. Verduijn et al. studied HD patients who were geno-
typed for the Thr256Ser polymorphism and found that carriers
of a serine allele displayed lower fetuin-A levels. A small in-
creased mortality risk was observed for the Thr/Ser and Ser/
Ser genotype compared with the Thr/Thr [87]. Also Axelsson
et al. found that fetuin-A (Cﬁ G); Thr256Ser gene polymor-
phisms inﬂuenced circulating levels of fetuin-A [88].
However Cozzolino et al. found that in both Italian HD pa-
tients and the control group, the distribution of fetuin-A gene
did not show signiﬁcant association between low serum fetuin-
A and fetuin-A (Cﬁ G); Thr256Ser gene polymorphism [89].
Also
Zeidan et al. demonstrated similar results [32].
Probably, the reason that some recent clinical results are
different from our ﬁndings may be explained by the differences
in races and other fetuin-A single nucleotide polymorphisms
not yet known may affect its serum level.
With fetuin-A being a negative acute phase glycoprotein, it
is plausible that fetuin-A links to VC by reﬂecting the risk of
inﬂammation. Persistent inﬂammation in dialysis patients
may serve as a catalyst and in the toxic uraemic milieu, mod-
ulates the effects of other concurrent risk factors, which would
thereby exacerbate the VC process [30,79]. As osteoporosis has
an important inﬂammatory component, the latter might be
part of the pathway linking VC and bone loss [60].
However beyond the effect of inﬂammation, the role of ser-
um fetuin-A level in VC may be far more complex than previ-
ously thought [80].
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